Genflow Biosciences PLC Announces 2024 Highlights
Rhea-AI Summary
Genflow Biosciences has reported key developments for 2024 in their aging-focused therapeutic programs. The company's MASH program (GF-1002) is advancing to pre-IND phase, partnering with Exothera SA for GMP manufacturing of clinical lots. For Werner Syndrome (GF-1003), they've developed proprietary liver organoids from human patient cells. The Dog Aging program (GF-1004) is initiating a six-month life extension clinical trial in collaboration with Syngene, expected to complete analysis by end of 2025.
Their Sarcopenia program (GF-1005) is progressing with myoblast progenitor studies in partnership with Université libre de Bruxelles, focusing on mitochondrial dysfunction. The company received support from the Belgian Government and has strengthened its research collaborations throughout the year.
Positive
- Partnership with Exothera SA for GMP manufacturing capabilities
- Development of proprietary human liver organoids for Werner Syndrome research
- Initiation of dog aging clinical trial with potential partnership opportunities
- Government support from Belgium for research advancement
Negative
- No immediate revenue generation from current research programs
- Clinical trial results and full analysis not expected until end of 2025
- Multiple programs in early stages requiring significant capital investment
Genflow Biosciences Plc
("Genflow" or "the Company")
A Look Back at an Exciting 2024
LONDON, UNITED KINGDOM / ACCESSWIRE / January 6, 2025 / 2024 has been an incredible year for Genflow as we advance our mission to develop novel therapeutics that promote a longer, healthier life.
Our focus on the SIRT6 gene and its potential to slow aging and delay age-related diseases has seen significant progress. This year, we've strengthened our leadership by collaborating with world-class researchers and laboratories, with generous support from the Belgian Government that has been instrumental in advancing our work.
Program Highlights
Throughout the year, our programs made significant strides, including:
MASH (GF-1002): We are advancing to the pre-IND phase of our preclinical development and have partnered with Exothera SA for GMP manufacturing of the clinical lot. Exothera, a specialized CDMO, provides end-to-end GMP manufacturing services for viral vectors, RNA therapeutics and vaccines, with state-of-the-art facilities in Belgium and the US.
Leveraging these innovative technologies and expertise, we are positioned to fast-track our progress and initiate the first proof-of-concept study of our gene therapy in patients with MASH. This milestone is a critical achievement for the Company, signaling our readiness to transition into clinical trials and showcasing the maturity and scalability of our therapeutic platform. Prior to commencing GMP manufacturing, we will ensure full regulatory compliance to reinforce confidence in our program among potential partners, investors, and regulatory agencies.
Werner Syndrome (GF-1003): We have developed a proprietary liver organoid derived from human cells of patients with Werner syndrome. Organoids are miniature, three-dimensional tissue models (grown in the lab) that mimic the structure and function of real organs.
Compared to using animal models, organoids offer several advantages: they are derived from human cells from patients affected with the disease, providing more accurate insights into human-specific biology; they reduce reliance on animals in research; and they allow for personalized disease modeling and drug testing tailored to individual patients.
Dog Aging (GF-1004): We are initiating a life extension clinical trial for aging dogs in collaboration with our contract research partner, Syngene. This six-month study will assess the potential of a veterinary version of our gene therapy to extend both the health span and lifespan of dogs. We expect to complete the full analysis of the trial by the end of 2025. Based on the outcomes, we may explore partnership opportunities or licensing agreements with veterinary specialty pharmaceutical companies.
Sarcopenia (GF-1005): We are making steady progress with our project aimed at addressing mitochondrial dysfunction observed in sarcopenia. This work focuses on restoring mitochondrial health as a key factor in combating the condition. The loading of myoblast progenitors with centSIRT6 is currently underway in collaboration with our partner, Université libre de Bruxelles (ULB). We are optimistic that these efforts will pave the way for innovative solutions to improve muscle health and combat sarcopenia effectively.
Looking Ahead
As we prepare for 2025, we are energized by the progress we've made and the opportunities ahead. Our commitment to tackling aging as a fundamental risk factor for chronic diseases remains steadfast. With continued collaboration and innovation, we are confident we will achieve great things in the coming year.
Thank you all for your trust and support on this journey. Our stakeholders' belief in what we're working towards means the world to us and we can't wait to share more exciting updates in the months to come!
Dr Eric Leire
CEO
Genflow Biosciences Plc.
Contacts
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
| |
|
|
Corporate Brokers |
| |
Capital Plus Partners Ltd |
| |
|
| |
Jon Critchley, +44 0203 821 6168 |
| |
|
|
|
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and Twitter/X.
DISCLAIMER
The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.
This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Forward-looking statements include all matters that are not historical facts. Forward looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.
Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on accesswire.com
FAQ
What are the main therapeutic programs in Genflow Biosciences (GENFF) pipeline for 2024?
When will Genflow Biosciences (GENFF) complete the dog aging clinical trial analysis?
What is the partnership between Genflow (GENFF) and Exothera SA for?
What breakthrough has Genflow (GENFF) achieved in Werner Syndrome research?
